Skip to main content
. 2024 Jan 10;19(1):e0295926. doi: 10.1371/journal.pone.0295926

Table 2. Alexithymia, self-compassion, and altered self-capacities scores by treatment group and baseline self-experience levels.

Therapy with placebo MDMA-assisted therapy Between-group difference in change scores
N Baseline N Follow-up Change4,5,7 N Baseline N Follow-up Change4,5,7 p-value6,7
Baseline TAS-201,2, mean (SD) 44 55.73 (10.64) 40 51.20 (11.47) -3.39 (1.57)* 46 53.00 (13.75) 42 41.62 (11.71) -12.06 (1.75)* < .0001*
    No alexithymia 18 45.56 (3.70) 17 43.41 (9.49) -6.24 (2.76)* 19 39.84 (7.91) 17 35.12 (8.30) -11.72 (3.22)* 0.35
    Alexithymia 26 62.77 (7.71) 23 56.96 (9.29) -1.51 (2.26) 27 62.26 (8.28) 25 46.04 (11.74) -12.85 (2.43)* < .0006*
Baseline SCS1,3, mean (SD) 44 2.18 (0.68) 40 2.51 (0.86) 0.24 (0.12)^ 46 2.38 (0.83) 42 3.50 (0.81) 1.08 (0.13)* < .0001*
    Moderate or High 14 2.98 (0.45) 13 3.22 (0.84) 0.38 (0.23) 19 3.22 (0.54) 18 3.76 (0.62) 0.76 (0.23)* .42
    Low 30 1.80 (0.38) 27 2.16 (0.64) 0.23 (0.16) 27 1.79 (0.35) 24 3.30 (0.88) 1.36 (0.20)* < .0001*
Baseline IASC1, mean (SD)
    Interpersonal Conflicts 44 2.57 (0.93) 40 2.27 (0.84) -0.25 (0.11)* 46 2.53 (0.99) 42 1.81 (0.58) -0.69 (0.12)* .0027*
          ≤ median 2.33 24 1.90 (0.33) 22 2.00 (0.64) -0.29 (0.16) 23 1.74 (0.29) 21 1.55 (0.49) -0.68 (0.17)* .21
      > median 20 3.36 (0.78) 18 2.61 (0.95) -0.20 (0.19) 23 3.33 (0.77) 21 2.07 (0.55) -0.72 (0.20)* .08
    Idealization-Disillusionment 44 2.25 (1.08) 40 1.86 (0.93) -0.31 (0.11)* 46 2.02 (0.99) 42 1.39 (0.59) -0.70 (0.12)* .0095*
          ≤ median 1.84 19 1.29 (0.22) 17 1.35 (0.57) -0.48 (0.19)* 26 1.29 (0.23) 24 1.12 (0.36) -0.69 (0.18)* .71
          > median 25 2.98 (0.89) 23 2.23 (0.97) -0.20 (0.17) 20 2.97 (0.76) 18 1.75 (0.65) -0.75 (0.21)* .05
    Abandonment Concerns 44 2.57 (1.01) 40 2.22 (0.99) -0.23 (0.13) 46 2.41 (1.14) 42 1.70 (0.80) -0.62 (0.14)* .0293*
      ≤ median 2.28 20 1.62 (0.34) 18 1.78 (0.87) -0.21 (0.24) 25 1.50 (0.37) 24 1.32 (0.54) -0.59 (0.24)* .39
      > median 24 3.37 (0.62) 22 2.59 (0.94) -0.26 (0.22) 21 3.50 (0.70) 18 2.20 (0.84) -0.64 (0.27)* .43
    Identity Impairment 44 5.50 (2.21) 40 4.70 (2.08) -0.66 (0.23)* 46 5.00 (1.97) 42 3.72 (1.71) -1.57 (0.25)* .0036*
      ≤ median 4.83 20 3.52 (0.79) 19 3.54 (1.00) -1.26 (0.41) 25 3.55 (0.91) 24 2.70 (0.75) -2.11 (0.38)* .1594
      > median 24 7.15 (1.55) 21 5.59 (1.62) -0.10 (0.38) 21 6.73 (1.42) 18 4.53 (1.81) -1.09 (0.41)* .1419
      Self-Awareness 44 3.22 (1.19) 40 2.85 (1.03) -0.29 (0.14)^ 46 2.97 (1.12) 42 2.08 (0.98) -0.96 (0.16)* .0010*
      ≤ median 3.00 23 2.23 (0.60) 21 2.48 (0.91) -0.01 (0.26) 23 2.01 (0.57) 20 1.65 (0.60) -0.66 (0.29)* .09
      > median 21 4.30 (0.56) 19 3.25 (1.01) -0.62 (0.28)* 23 3.93 (0.55) 22 2.46 (1.10) -1.14 (0.25)* .28
    Identity Diffusion 44 2.28 (1.21) 40 1.78 (0.85) -0.36 (0.10)* 46 2.03 (1.05) 42 1.40 (0.69) -0.61 (0.12)* .0757
      ≤ median 1.75 22 1.30 (0.31) 21 1.38 (0.55) -0.36 (0.18)* 25 1.20 (0.27) 23 1.09 (0.21) -0.60 (0.18)* .58
      > median 22 3.26 (0.93) 19 2.21 (0.92) -0.36 (0.20) 21 3.02 (0.70) 19 1.79 (0.86) -0.63 (0.20)* .61
    Susceptibility to Influence 44 2.04 (0.92) 40 1.76 (0.73) -0.14 (0.09) 46 1.90 (0.86) 42 1.28 (0.41) -0.55 (0.10)* .0012*
      ≤ median 1.78 23 1.37 (0.26) 21 1.49 (0.56) -0.29 (0.14)^ 23 1.22 (0.22) 20 1.17 (0.42) -0.58 (0.16)* .33
      > median 21 2.76 (0.83) 19 2.05 (0.80) 0.02 (0.15) 23 2.58 (0.69) 22 1.38 (0.37) -0.56 (0.15)* .0099*
      Affect Dysregulation 44 5.85 (2.14) 40 4.70 (2.08) -0.96 (0.27)* 46 5.48 (2.28) 42 3.72 (1.71) -1.75 (0.30)* .0349*
        ≤ median 5.80 22 4.1 (1.04) 21 3.74 (1.69) -1.30 (0.44)* 23 3.46 (0.88) 21 2.85 (1.16) -1.92 (0.53)* .6381
        > median 22 7.61 (1.35) 19 5.76 (1.97) -0.54 (0.51) 23 7.49 (1.16) 21 4.59 (1.74) -1.63 (0.50)* .1763
      Affect Instability 44 2.81 (1.10) 40 2.29 (0.99) -0.40 (0.13)* 46 2.57 (1.23) 42 1.84 (0.84) -0.76 (0.15)* .0454*
        ≤ median 2.50 22 1.92 (0.48) 21 1.82 (0.67) -0.55 (0.22)* 26 1.62 (0.46) 24 1.52 (0.68) -0.73 (0.25)* .88
        > median 22 3.70 (0.76) 19 2.80 (1.04) -0.24 (0.24) 20 3.81 (0.65) 18 2.26 (0.87) -0.84 (0.26)* .12
      Affect Skill Deficit 44 3.04 (1.24) 40 2.41 (1.24) -0.56 (0.15)* 46 2.90 (1.17) 42 1.88 (0.92) -0.98 (0.17)* .0424*
        ≤ median 3.00 22 1.99 (0.69) 20 1.60 (0.60) -0.41 (0.57)* 24 1.97 (0.67) 22 1.50 (0.65) -0.43 (0.83)* 1.0
        > median 22 4.09 (0.60) 20 3.22 (1.19) -0.84 (1.45) 22 3.93 (0.59) 20 2.29 (1.00) -1.60 (0.92)* .02*
    Tension Reduction Activities 44 1.88 (0.57) 40 1.66 (0.48) -0.19 (0.07)* 46 1.85 (0.71) 42 1.40 (0.45) -0.42 (0.08)* .0206*
        ≤ median 1.78 20 1.43 (0.20) 18 1.54 (0.43) -0.13 (0.12) 26 1.34 (0.26) 24 1.26 (0.41) -0.37 (0.12)* .30
        > median 24 2.25 (0.50) 22 1.75 (0.52) -0.24 (0.10)* 20 2.52 (0.53) 18 1.60 (0.44) -0.47 (0.14)* .36

1 Abbreviations: TAS-20 = Toronto Alexithymia Scale; SCS = Self-Compassion Scale; IASC = Inventory of Altered Self-Capacities; ASC = Altered Self-Capacities

2 TAS-20 cutoff scores: no alexithymia ≤50; borderline alexithymia (51–60); alexithymia (≥61) (Bagby et al. 1994)

3 SCS cutoff scores: low (1–2.4); moderate (2.5–3.4); high (3.5–5.0) (Neff 2003)

4 Change scores are Least Square Means (Standard Errors)

5 (*) = indicates a p-value of < .05 for within-subjects comparison of baseline vs. follow-up scores; (^) p = 0.05

6 (*) indicates a p-value of < .05 for between-group subjects’ comparison of Therapy with placebo change scores vs. MDMA-assisted therapy change scores; (^) p = 0.05

7 All models adjusted for baseline CAPS-5 Dissociative Subtype (Yes/ No), baseline self-experience score (TAS-20, SCS, or IASC factor score), and corrected for multiple comparisons using Tukey’s HSD